Literature DB >> 3569338

High or low dose radioiodine ablation of thyroid remnants?

H Creutzig.   

Abstract

The need for high dose radioiodine for ablation of remnants in patients with thyroid cancer is still in question. We compared the effectiveness of high and low dose 131I for ablation in patients in a prospective randomized study after surgical thyroidectomy. Twenty patients with differentiated pT2-3NoMo thyroid cancer were studied. The uptake was 5%-10% at 24 h. Ten patients received 100 mCi, the others 30 mCi 131I. Three months later all patients received a therapeutic dose of 150 mCi 131I. Another twenty patients with known distant metastases (pulmonary and/or bone) of differentiated thyroid cancer were studied. The remnant uptake was between 4%-10%. Ten patients received 300 mCi and ten 30 mCi 131I as ablation dose. Three months later all received 300 mCi 131I. The uptake at day seven was calculated for the same metastases from a whole body scan after both treatments. If effective ablation was defined as 24 h uptake in the remnant of less than 1%, then the ablation was effective in eight out of ten of the high dose and in seven out of ten of the low dose group. In pT2-3, N X M1 patients the ablation was effective in seven out of ten cases in both groups. If "effective" ablation was defined as an uptake of less than 0.5%, then the ablation was effective both in NoMo and in N X M1 patients in five out of ten with low dose and in six out of ten with high dose ablation treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3569338     DOI: 10.1007/bf00620474

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  10 in total

1.  Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer.

Authors:  K D McCowen; R A Adler; N Ghaed; T Verdon; F D Hofeldt
Journal:  Am J Med       Date:  1976-07       Impact factor: 4.965

2.  Post-operative diagnosis and therapy of thyroid carcinoma by nuclear medicine.

Authors:  H Hundeshagen
Journal:  Eur J Nucl Med       Date:  1983

3.  Thyroid remnant ablation: questionable pursuit of an ill-defined goal.

Authors:  J Snyder; C Gorman; P Scanlon
Journal:  J Nucl Med       Date:  1983-08       Impact factor: 10.057

Review 4.  Radionuclide diagnosis and therapy of thyroid cancer: current status report.

Authors:  J E Freitas; M D Gross; S Ripley; B Shapiro
Journal:  Semin Nucl Med       Date:  1985-04       Impact factor: 4.446

5.  Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer.

Authors:  C C Kuni; W C Klingensmith
Journal:  Radiology       Date:  1980-12       Impact factor: 11.105

6.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.

Authors:  H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger
Journal:  N Engl J Med       Date:  1983-10-20       Impact factor: 91.245

7.  [Therapeutic results of malignant goiter 1960-1980. Significance of percutaneous radiotherapy in well differentiated carcinomas].

Authors:  B Leisner; G Degelmann; W Dirr; W Kanitz; U Büll; H Langhammer; J Lissner; H W Pabst
Journal:  Dtsch Med Wochenschr       Date:  1982-11-12       Impact factor: 0.628

8.  An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.

Authors:  W H Beierwaltes; R Rabbani; C Dmuchowski; R V Lloyd; P Eyre; S Mallette
Journal:  J Nucl Med       Date:  1984-12       Impact factor: 10.057

9.  Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation.

Authors:  L J Degroot; M Reilly
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

10.  Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma.

Authors:  A R Siddiqui; J Edmondson; H N Wellman; R C Hamaker; R E Lingeman; H M Park; C C Johnston
Journal:  Clin Nucl Med       Date:  1981-04       Impact factor: 7.794

  10 in total
  13 in total

1.  RADIOIODINE THERAPY FOR DIFFERENTIATED THYROID CARCINOMA : INHS ASVINI EXPERIENCE.

Authors:  J K Bhagat; Brig Dinesh Prasad
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

Review 3.  Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials.

Authors:  Peizhun Du; Xuelong Jiao; Yanbing Zhou; Yu Li; Shan Kang; Dongfeng Zhang; Jizhun Zhang; Liang Lv; Rajan Patel
Journal:  Endocrine       Date:  2014-07-06       Impact factor: 3.633

4.  The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

Authors:  Ken Watanabe; Mayuki Uchiyama; Kunihiko Fukuda
Journal:  Jpn J Radiol       Date:  2017-06-15       Impact factor: 2.374

Review 5.  Novel Approaches to Thyroid Cancer Treatment and Response Assessment.

Authors:  Ravinder K Grewal; Alan Ho; Heiko Schöder
Journal:  Semin Nucl Med       Date:  2016-03       Impact factor: 4.446

6.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 7.  Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Authors:  Y Fang; Y Ding; Q Guo; J Xing; Y Long; Z Zong
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

8.  A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.

Authors:  T Ben Ghachem; I Yeddes; I Meddeb; A Bahloul; A Mhiri; I Slim; M F Ben Slimene
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-25       Impact factor: 2.503

9.  Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?

Authors:  Ajit S Shinto; K K Kamaleshwaran; Deepu K Shibu; K Vyshak; Joppy Antony
Journal:  World J Nucl Med       Date:  2013-05

10.  Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.

Authors:  Hanna O Mäenpää; Jorma Heikkonen; Leila Vaalavirta; Mikko Tenhunen; Heikki Joensuu
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.